Form 4: Bristol-Myers Squibb Executive Hickey Reports Stock Transactions

Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reports the vesting of restricted stock units and subsequent tax withholding.

Summary

• On February 1, 2025, Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reported transactions involving Bristol-Myers Squibb common stock.
• Hickey vested 10,078 restricted stock units, which converted into an equal number of common shares.
• 3,725 shares were withheld for payment of taxes at a price of $58.95 per share.
• Following these transactions, Hickey directly owns 7,133 shares of common stock and indirectly owns 91 shares through a spouse.
• He also directly owns 20,158 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel and their alignment with shareholder interests.

Stakeholder Impact

• The filing provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transaction, Restricted Stock Units, Bristol-Myers Squibb, BMY, Hickey, RayzeBio